Last reviewed · How we verify

Hugel — Portfolio Competitive Intelligence Brief

Hugel pipeline: 2 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 2 Phase 3 0 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Botulinum Toxin Type A Injection [Botox] Botulinum Toxin Type A Injection [Botox] marketed
Botulinum toxin type A injection Botulinum toxin type A injection marketed Neurotoxin; botulinum toxin preparation SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology; Aesthetics; Dermatology
Hugeltox Hugeltox phase 3 Other
Botulinum Toxin Type A Injection [HG102] Botulinum Toxin Type A Injection [HG102] phase 3 Neurotoxin; botulinum toxin preparation SNARE proteins (synaptobrevin/VAMP); acetylcholine release machinery Neurology; Aesthetics; Pain Management

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Hugel:

Cite this brief

Drug Landscape (2026). Hugel — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/hugel. Accessed 2026-05-14.

Related